bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 164.9% in February

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 105,183 shares, a growth of 164.9% from the January 29th total of 39,712 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily volume of 241,624 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 241,624 shares, the days-to-cover ratio is currently 0.4 days. Approximately 2.4% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at approximately $49,000. Sabby Management LLC bought a new position in bioAffinity Technologies during the 3rd quarter worth $719,000. Finally, Geode Capital Management LLC acquired a new position in bioAffinity Technologies in the 4th quarter valued at $36,000. 1.64% of the stock is owned by institutional investors.

bioAffinity Technologies Trading Up 1.9%

Shares of bioAffinity Technologies stock opened at $1.06 on Friday. bioAffinity Technologies has a 52-week low of $0.69 and a 52-week high of $46.53. The stock has a market cap of $4.77 million, a PE ratio of -0.05 and a beta of 2.44. The firm has a 50-day moving average of $1.17 and a 200-day moving average of $2.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.65.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.